Published in J Neurochem on February 27, 2010
Interaction of membrane/lipid rafts with the cytoskeleton: impact on signaling and function: membrane/lipid rafts, mediators of cytoskeletal arrangement and cell signaling. Biochim Biophys Acta (2013) 1.37
Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients. J Affect Disord (2011) 1.07
Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection. J Clin Invest (2014) 1.06
Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators. Bioorg Med Chem Lett (2011) 0.95
Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci (2015) 0.92
Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for Alzheimer's disease. J Exp Med (2015) 0.91
Calcineurin and glial signaling: neuroinflammation and beyond. J Neuroinflammation (2014) 0.85
Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases. Future Med Chem (2012) 0.84
Glia: an emerging target for neurological disease therapy. Stem Cell Res Ther (2012) 0.81
Neuron-astrocyte interactions in neurodegenerative diseases: Role of neuroinflammation. Clin Exp Neuroimmunol (2015) 0.76
DJ-1 deficiency impairs glutamate uptake into astrocytes via the regulation of flotillin-1 and caveolin-1 expression. Sci Rep (2016) 0.75
Esterification of 24S-OHC induces formation of atypical lipid droplet-like structures, leading to neuronal cell death. J Lipid Res (2016) 0.75
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology (1991) 23.01
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
Rafts defined: a report on the Keystone Symposium on Lipid Rafts and Cell Function. J Lipid Res (2006) 6.11
Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med (1992) 3.71
Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci (2006) 3.69
Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol (1995) 3.66
Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 3.61
Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat Cell Biol (2005) 2.91
Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A (1996) 2.48
Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci U S A (2006) 2.45
Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol (2003) 2.10
Brain glutamate transporter proteins form homomultimers. J Biol Chem (1996) 2.01
Glutamate transporters are oxidant-vulnerable: a molecular link between oxidative and excitotoxic neurodegeneration? Trends Pharmacol Sci (1998) 1.65
Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet (2003) 1.53
Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res (2000) 1.51
Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease. Ann Neurol (1996) 1.50
Messenger RNA oxidation is an early event preceding cell death and causes reduced protein expression. FASEB J (2007) 1.49
Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain. J Comp Neurol (2008) 1.47
Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol (1997) 1.42
Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis (2007) 1.36
Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro. J Biol Chem (1997) 1.34
Association of excitatory amino acid transporters, especially EAAT2, with cholesterol-rich lipid raft microdomains: importance for excitatory amino acid transporter localization and function. J Biol Chem (2004) 1.32
A novel action of alzheimer's amyloid beta-protein (Abeta): oligomeric Abeta promotes lipid release. J Neurosci (2001) 1.26
24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res (2001) 1.16
Translational control of glial glutamate transporter EAAT2 expression. J Biol Chem (2006) 1.14
On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci Lett (2001) 1.05
Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease. J Neurochem (1988) 0.97
Changes in the cellular distribution of glutamine synthetase in Alzheimer's disease. J Neurosci Res (2001) 0.96
Human glioma cells and undifferentiated primary astrocytes that express aberrant EAAT2 mRNA inhibit normal EAAT2 protein expression and prevent cell death. Mol Cell Neurosci (2002) 0.94
Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's disease. J Neurosci Res (1999) 0.94
Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease. Hum Genet (2004) 0.92
Polymorphisms of cholesterol metabolism genes CYP46 and ABCA1 and the risk of sporadic Alzheimer's disease in Chinese. Brain Res (2007) 0.87
Region-specific loss of glutamate innervation in Alzheimer's disease. Neurosci Lett (1987) 0.86
Caveolin and GLT-1 gene expression is reciprocally regulated in primary astrocytes: association of GLT-1 with non-caveolar lipid rafts. Glia (2005) 0.85
Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type. Proc Natl Acad Sci U S A (1990) 0.83
Regional changes in [3H]D-aspartate and [3H]TCP binding sites in Alzheimer's disease brains. Brain Res (1988) 0.81
Sodium dependent D-[3H]aspartate binding in cerebral cortex in patients with Alzheimer's and Parkinson's diseases. Neurosci Lett (1987) 0.81
Association of CYP46 intron 2 polymorphism in Finnish Alzheimer's disease samples and a global scale summary. J Neurol Neurosurg Psychiatry (2006) 0.80
Regional distribution of pre- and postsynaptic glutamatergic function in Alzheimer's disease. Brain Res (1988) 0.80
Polymorphism in the cholesterol 24S-hydroxylase gene (CYP46A1) associated with the APOEpsilon3 allele increases the risk of Alzheimer's disease and of mild cognitive impairment progressing to Alzheimer's disease. Dement Geriatr Cogn Disord (2005) 0.79
Sodium-dependent glutamate binding in senile dementia. Neurobiol Aging (1987) 0.78
Variant forms of neuronal glutamate transporter sites in Alzheimer's disease cerebral cortex. J Neurochem (1995) 0.78
Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet (2003) 1.53
Messenger RNA oxidation occurs early in disease pathogenesis and promotes motor neuron degeneration in ALS. PLoS One (2008) 1.34
Functional P2Y2 nucleotide receptors mediate uridine 5'-triphosphate-induced intimal hyperplasia in collared rabbit carotid arteries. Circulation (2002) 1.27
The P2Y2 nucleotide receptor mediates UTP-induced vascular cell adhesion molecule-1 expression in coronary artery endothelial cells. J Biol Chem (2003) 1.18
Identification of translational activators of glial glutamate transporter EAAT2 through cell-based high-throughput screening: an approach to prevent excitotoxicity. J Biomol Screen (2010) 1.14
Translational control of glial glutamate transporter EAAT2 expression. J Biol Chem (2006) 1.14
P2Y nucleotide receptor interaction with alpha integrin mediates astrocyte migration. J Neurochem (2005) 1.12
Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection. J Clin Invest (2014) 1.06
P2X7 receptors stimulate AKT phosphorylation in astrocytes. Br J Pharmacol (2004) 1.05
Hemangioblastoma of the cerebellopontine angle. Arch Otolaryngol Head Neck Surg (2010) 1.02
Frequency, molecular pathology and potential clinical significance of partial chromosome 3 aberrations in uveal melanoma. Mod Pathol (2011) 1.00
Postmortem magnetic resonance imaging to guide the pathologic cut: individualized, 3-dimensionally printed cutting boxes for fixed brains. J Neuropathol Exp Neurol (2014) 0.99
Extradural dermoid tumor of the petrous apex. Case report. J Neurosurg (2007) 0.96
Structure-activity relationship study of pyridazine derivatives as glutamate transporter EAAT2 activators. Bioorg Med Chem Lett (2011) 0.95
Human glioma cells and undifferentiated primary astrocytes that express aberrant EAAT2 mRNA inhibit normal EAAT2 protein expression and prevent cell death. Mol Cell Neurosci (2002) 0.94
Gerstmann-Sträussler-Scheinker: a new phenotype with 'curly' PrP deposits. J Neuropathol Exp Neurol (2006) 0.92
Optic disc edema from remote uveal melanoma. JAMA Ophthalmol (2013) 0.90
High resolution ultra high field magnetic resonance imaging of glioma microvascularity and hypoxia using ultra-small particles of iron oxide. Invest Radiol (2009) 0.86
P2 receptors in atherosclerosis and postangioplasty restenosis. Purinergic Signal (2007) 0.84
Glutamate transporter EAAT2: a new target for the treatment of neurodegenerative diseases. Future Med Chem (2012) 0.84
Method for novel anti-cancer drug development using tumor explants of surgical specimens. J Vis Exp (2011) 0.83
The importance of preclinical trial timing - a potential reason for the disconnect between mouse studies and human clinical trials in ALS. CNS Neurosci Ther (2012) 0.82
Metastasis development at the site of cervical spine arthrodesis. Acta Neurochir (Wien) (2009) 0.79
Spinal myxopapillary ependymoma metastatic to bilateral internal auditory canals. Ann Otol Rhinol Laryngol (2008) 0.79
P2 receptors in atherosclerosis and postangioplasty restenosis. Purinergic Signal (2006) 0.79
Solitary pituitary sarcoidosis with normal endocrine function: case report. J Neurosurg (2008) 0.77
Peripheral neuropathy in a family with Sandhoff disease and SH3TC2 deficiency. J Neurol (2015) 0.76
Type II (adult onset) Alexander disease in a paraplegic male with a rare D128N mutation in the GFAP gene. Clin Neuropathol (2015) 0.75
Brain tumor imaging and cancer management: the neuro-oncologists perspective. Top Magn Reson Imaging (2006) 0.75
Surgical Management of Carney Complex-Associated Pituitary Pathology. Neurosurgery (2016) 0.75
Erratum to: P2 receptors in atherosclerosis and postangioplasty restenosis. Purinergic Signal (2015) 0.75